CELU
Celularity Inc
+0.03 (+2.71%)1.33USD38.9K成交股數38.4M市值–本益比(近四季)1.4股價營收比-43.2%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 | 22Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 5.3M-43% | 5.7M-53% | 11.4M-22% | 18.1M+379% | 9.3M+216% | 12.1M+208% | 14.7M+256% | 3.8M-8% | 2.9M | 3.9M | 4.1M | 4.1M |
| 營業成本 | 3.9M | 5.2M | 3.6M | 7.3M | 3.9M | 2.1M | 1.6M | 3.6M | 802K | 2.0M | – | – |
| 毛利 | 1.4M-75% | 494K-95% | 7.9M-40% | 10.8M+5764% | 5.4M+153% | 10.0M+417% | 13.0M-1266% | 184K-106% | 2.1M | 1.9M | −1.1M | −3.1M |
| 毛利率 | 26.1% | 8.6% | 68.9% | 59.5% | 58.2% | 82.5% | 88.8% | 4.9% | 72.7% | 49.1% | -27.1% | -74.4% |
| 研發費用 | 4.6M | 3.4M | 3.7M | 3.8M | 3.9M | 3.8M | 5.8M | 5.2M | 8.6M | 17.0M | 11.0M | 20.4M |
| 銷售管理費用 | 9.3M | 12.6M | 14.3M | 16.1M | 12.7M | 15.9M | 14.0M | 10.7M | 12.8M | 13.9M | 19.1M | 14.9M |
| 營業利益 | −12.9M+12% | −15.9M+56% | −10.5M+42% | −9.3M-91% | −11.5M-73% | −10.2M-84% | −7.4M-142% | −99.3M+1658% | −42.5M | −63.9M | 17.5M | −5.6M |
| 營業利益率 | -244.1% | -276.6% | -91.8% | -51.2% | -124.0% | -84.0% | -50.2% | -2,621.7% | -1,445.7% | -1,623.1% | 423.5% | -136.5% |
| 稅後淨利 | −23.1M+43% | −24.5M+278% | −19.8M-10% | −13.3M-86% | −16.1M-66% | −6.5M-90% | −22.0M-190% | −93.9M-2056% | −47.9M | −64.0M | 24.4M | 4.8M |
| 淨利率 | -436.7% | -427.5% | -172.9% | -73.3% | -173.2% | -53.6% | -149.9% | -2,479.6% | -1,632.0% | -1,626.9% | 591.8% | 116.1% |
| 稀釋 EPS | -0.88+21% | -1.02+240% | -0.84-18% | -0.58-88% | -0.73-73% | -0.30-93% | -1.03-195% | -4.98-16700% | -2.72 | -4.12 | 1.08 | 0.03 |
| 稀釋股數 | 26.3M | 24.0M | 23.5M | 21.9M | 22.0M | 21.8M | 21.4M | 18.8M | 17.7M | 15.5M | 15.0M | 151M |
資產負債表 期末餘額
| 科目 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 | 22Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 120K | 863K | 293K | 738K | 133K | 467K | 1.9M | 273K | 3.1M | 8.5M | 14.0M | 42.6M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | 2.6M | 4.4M | 6.2M | 5.4M | 4.0M | 2.9M | 3.7M | 4.9M | 5.7M | 5.5M | 5.3M | 5.2M |
| 總資產 | 114M | 120M | 129M | 133M | 129M | 135M | 144M | 157M | 246M | 362M | 401M | 437M |
| 有息負債 | 35.7M | – | – | – | – | – | – | – | 17.0M | 4.7M | – | – |
| 總負債 | 134M | 146M | 134M | 124M | 112M | 108M | 113M | 127M | 128M | 207M | 202M | 273M |
| 股東權益 | −20.1M | −25.5M | −5.5M | 8.8M | 17.3M | 27.8M | 31.2M | 30.2M | 119M | 156M | 199M | 164M |
| 負債比 | 117.6% | 121.2% | 104.3% | 93.3% | 86.6% | 79.5% | 78.3% | 80.8% | 51.9% | 57.1% | 50.4% | 62.4% |
| 淨現金(現金 − 有息負債) | −35.6M | – | – | – | – | – | – | – | −13.9M | 3.8M | – | – |
現金流量表 單季
| 科目 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 | 22Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | −3.0M-32% | – | – | – | −4.4M | – | – | −15.0M | – | – |
| 資本支出 | – | – | – | – | – | – | 39K | – | – | 209K | – | – |
| 自由現金流 | – | – | – | – | – | – | −4.4M | – | – | −15.2M | – | – |
| 折舊攤銷 | – | – | 1.8M | 2.7M | 1.5M | 1.5M | 2.2M | 1.8M | 1.8M | 2.4M | 3.5M | 1.8M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | -30.3% | – | – | -386.4% | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 26.6M
| Degenerative Disease | 17.3M | 65.2% | -64.2% |
|---|---|---|---|
| Biobanking | 5.4M | 20.5% | +5.7% |
| Cell Therapy | 3.8M | 14.3% | +453.3% |
產品／服務2025 年度 · 26.6M
| 產品 | 13.2M | 49.6% | -62.7% |
|---|---|---|---|
| License Royalty And Other | 7.9M | 29.9% | -42.2% |
| 服務 | 5.4M | 20.5% | +5.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 26.6M | -51.0% | −91.7M | -345.4% | -3.59 | – |
| FY2024 | 54.2M | +138.1% | −57.9M | -106.8% | -2.64 | −6.6M |
| FY2023 | 22.8M | +26.7% | −196M | -862.0% | -11.02 | −39.7M |
| FY2022 | 18.0M | -15.7% | 14.2M | 79.0% | 0.95 | −143M |
| FY2021 | 21.3M | +49.4% | −100M | -469.3% | -1.49 | −116M |
| FY2020 | 14.3M | – | −208M | -1,458.4% | -11.31 | −91.0M |
| FY2019 | – | – | 5.9M | –% | 0.10 | – |